skip to content.

Private investors

Artemis Alpha Trust plc

All data as at 31 March 2016 except where specified
  • Summary
  • Performance
  • Composition
  • Key facts
  • Investment insights
  • Literature
  • How to invest

The fund’s aims

The fund aims to achieve above average rates of total return over the longer term and to achieve a growing dividend stream.

Investment policy

The company's investment portfolio comprises mainly UK and selected international equities, with the potential for investment in limited liability hedge funds, cash and bonds, unquoted investments, derivative instruments and other investments and securities as appropriate.

Current prices

Share price (ordinary)228.00p
Share price (subscription)6.25p
Dividend yield1.6%

Fund manager review

The recovery in the UK market that began in late February carried over into March. Helped by a rebound in the energy sector and by a bid for one of its largest holdings, the Company’s net asset value rose by slightly more than the All-Share.

In March, oil markets began to recoup some of their losses with the result that holdings such Africa Oil, Cairn Energy and African Petroleum rallied sharply.

At around 7% of the portfolio, the Company’s exposure to the energy sector is smaller than once it was. Even that modest degree of exposure was unhelpful last year as the price of crude tumbled. In March, oil markets began to recoup some of their losses with the result that holdings such Africa Oil, Cairn Energy and African Petroleum rallied sharply. None are large positions, but their gains were so dramatic (African Petroleum’s share price almost doubled) that the oil & gas sector made the largest contribution to returns. In the short term, our E&P stocks will remain at the mercy of volatile commodity markets. Over the longer term, however, we think their recovery has further to go.

The single largest contribution in March, however, came from Skyepharma. In recognition of the commercial potential of its innovative asthma treatments, it is one of the Company’s largest holdings. It announced an all-share merger with rival Vectura. The deal will create a new leader in respiratory medicine and values Skyepharma at 410p a share, a 4% premium to its price before the news broke.

Value of £100 invested at launch to 31 March 2016

Value of £100 invested at launch to 31 March 2016

Relative performance, value of £100 invested on 30 May 2003, the date Artemis was appointed as investment manager.
Source: Artemis/Lipper Limited, bid to bid in sterling with net income reinvested. All figures show total returns. Past performance is not a guide to future performance.

Asset allocation

Asset allocation

Without cash. The figures above include adjustments to the unquoted investment holdings made after the period end. Source: Artemis as at 31 March 2016. Please note figures may not add up to 100% due to rounding.

Email this article:





CAPTCHA Image
Refresh
Security Code

Risk warnings

This information does not constitute an offer, invitation or solicitation to deal in securities.

The value of shares in Artemis Alpha Trust PLC, and any income from them, can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. Stockmarket prices, currencies and interest rates can move irrationally and can be affected unpredictably by diverse factors, including political and economic events.

How the shares have performed in the past is not a guide to how they will perform in the future.

A proportion of the investment trust may be invested in emerging markets. Investment in emerging markets can involve greater risk than is customarily associated with more mature markets meaning above average price movements both positive and negative can be expected.

The investment trust may invest in the securities of smaller and/or medium sized companies. This can involve greater risk than is customarily associated with investment in larger, more established companies. The market for securities in smaller companies is often less liquid than that for securities in larger companies, meaning above average price movements both positive and negative can be expected.

The investment trust may borrow money in order to make further investments, which is known as 'gearing'. This can enhance investment returns in rising markets but conversely may reduce returns in falling markets.

FTSE International Limited (“FTSE”) © FTSE 2015. “FTSE®” is a trademark of the London Stock Exchange Group companies and is used by FTSE International Limited under licence. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE data is permitted without FTSE’s express written consent.

This information is issued by Artemis Fund Managers Limited which is authorised and regulated by the Financial Conduct Authority (www.fca.org.uk), 25 The North Colonnade, Canary Wharf, London E14 5HS.

Financial advisers and retail investors
The Company currently conducts its affairs so that the ordinary and subscription shares in issue can be recommended by financial advisers to ordinary retail investors in accordance with the Financial Conduct Authority’s (“FCA’s”) rules in relation to non-mainstream investment products and intends to do so for the foreseeable future. The ordinary and subscription shares are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

UK personal investors

I confirm that I am a UK personal investor and that I agree to and will comply with the terms and conditions of use of this website.